- Trials with a EudraCT protocol (1,739)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
1,739 result(s) found.
Displaying page 28 of 87.
EudraCT Number: 2010-018370-21 | Sponsor Protocol Number: C-II-007 | Start Date*: 2010-05-27 | |||||||||||
Sponsor Name:CESAR Central European Society for Anticancer Drug Research EWIV | |||||||||||||
Full Title: Phase I/II study with Temsirolimus versus no add-on in patients with castration resistant prostate cancer (CRPC) receiving first-line Docetaxel chemotherapy CESAR Study in Prostrate Cancer wi... | |||||||||||||
Medical condition: castration resistant prostate cancer (CRPC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004998-83 | Sponsor Protocol Number: MUS92579_2057_1 | Start Date*: 2012-04-04 | |||||||||||
Sponsor Name:Merz Pharmaceuticals GmbH | |||||||||||||
Full Title: A Double-Blind, Randomized, Dose Selection Vehicle–Controlled Multicenter Clinical Study for Evaluation of the Safety, Tolerability, Efficacy, and Pharmacokinetics of topical Neramexane in Subjects... | |||||||||||||
Medical condition: Moderate to severe acne | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001852-20 | Sponsor Protocol Number: UV1/hTERT-2012-L | Start Date*: 2013-01-17 | |||||||||||
Sponsor Name:Oslo University Hospital | |||||||||||||
Full Title: A PHASE I/IIa STUDY OF UV1 VACCINATION IN PATIENTS WITH NON-SMALL CELL LUNG CANCER | |||||||||||||
Medical condition: Patient with metastatic Non Small Cell Lung Cancer (NSCLC) stage IV. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005660-18 | Sponsor Protocol Number: PH-IUD-01 | Start Date*: 2012-03-26 | |||||||||||
Sponsor Name:Pharmanest AB | |||||||||||||
Full Title: An open label pharmcokinetic study of a topical formulation of lidocaine (SHACT) for pain relief in women receiving an Intra Uterine Device. | |||||||||||||
Medical condition: Pain during insertion of an intra uterine device | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-005157-23 | Sponsor Protocol Number: DART | Start Date*: 2013-05-21 | ||||||||||||||||||||||||||
Sponsor Name:Fondazione IRCCS Istituto Nazionale Tumori | ||||||||||||||||||||||||||||
Full Title: A Phase I/II Study of Danusertib in Combination with Romidepsin in Adult Patients with Mature Peripheral T Cell Lymphoma (PTCL) | ||||||||||||||||||||||||||||
Medical condition: (Ph I) Relapsed or refractory Hodgkin (HL) and Non Hodgkin lymphoma (NHL) in patients in the absence, unable ot who have been refused to undergo alternative salvage regimens. (Ph II) Relapsed or r... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-000695-42 | Sponsor Protocol Number: HGB-205 | Start Date*: 2012-12-31 | |||||||||||
Sponsor Name:bluebird bio, Inc. | |||||||||||||
Full Title: A Phase I/II Open Label Study Evaluating the Safety and Efficacy of Gene Therapy of the β-Hemoglobinopathies (Sickle Cell Anemia and β-Thalassemia Major) by Transplantation of Autologous CD34+ Stem... | |||||||||||||
Medical condition: Severe sickle cell anemia and transfusion-dependent beta-thalassemia major. This study will enroll patients who are eligible for an allogeneic hematopoietic stem cell transplant (HSCT) but do not... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004747-23 | Sponsor Protocol Number: BPC01-001 | Start Date*: 2014-01-17 | |||||||||||
Sponsor Name:Bionor Pharma ASA | |||||||||||||
Full Title: An Open Phase I/IIa Study to Evaluate the Safety and Effect of Therapeutic HIV-1 Immunization using Vacc-4x + rhuGM-CSF, and HIV-1 Reactivation using Romidepsin, on the Viral Reservoir in Virologic... | |||||||||||||
Medical condition: HIV-infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-004302-26 | Sponsor Protocol Number: 201350 | Start Date*: 2014-09-05 | |||||||||||
Sponsor Name:Santen Oy | |||||||||||||
Full Title: A phase I study to evaluate the pharmacokinetics, safety and tolerability of preservative free tafluprost ophthalmic solution (0.0015%) in pediatric patients diagnosed with glaucoma or ocular hyper... | |||||||||||||
Medical condition: Glaucoma or Ocular Hypertension | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) HU (Completed) SK (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004043-23 | Sponsor Protocol Number: IDX-04B-001 | Start Date*: 2013-11-13 | |||||||||||
Sponsor Name:Idenix Pharmaceuticals Inc. | |||||||||||||
Full Title: A Phase I/IIa Study Assessing Single and Multiple Doses of IDX21437 in Healthy and HCV-Infected Subjects | |||||||||||||
Medical condition: Hepatitis C virus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-003784-42 | Sponsor Protocol Number: RV-MM-PI-278 | Start Date*: 2008-11-24 | |||||||||||
Sponsor Name:University Medical Center Hamburg-Eppendorf | |||||||||||||
Full Title: Dose-finding study of lenalidomide as maintenance therapy in multiple myeloma after allogeneic stem cell transplantation | |||||||||||||
Medical condition: Multiple Myeloma patients who received allogeneic stem cell transplantation (100 to 180 days ago) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-004429-26 | Sponsor Protocol Number: Atu027-I-02 | Start Date*: 2013-02-25 | ||||||||||||||||
Sponsor Name:Silence Therapeutics GmbH | ||||||||||||||||||
Full Title: A Phase Ib/IIa study of combination therapy with Gemcitabine and Atu027 in subjects with locally advanced or metastatic pancreatic adenocarcinoma | ||||||||||||||||||
Medical condition: Locally advanced or metastatic pancreatic adenocarcinoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-001012-11 | Sponsor Protocol Number: NAT-2017-01 | Start Date*: 2017-08-01 | ||||||||||||||||
Sponsor Name:Acerus Biopharma Inc. | ||||||||||||||||||
Full Title: A multicenter, open label, variable dose, two arm pilot paediatric phase 1 PK study to evaluate testosterone nasal gel (4.5% w/w) in hypogonadal boys | ||||||||||||||||||
Medical condition: Primary and secondary hypogonadism | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005609-34 | Sponsor Protocol Number: CNIO-BR-008 | Start Date*: 2016-04-26 | |||||||||||
Sponsor Name:Fundación CRIS de investigación para vencer el cáncer | |||||||||||||
Full Title: Abrogation of chronic monoclonal antibody treatment-induced T-cell exhaustion with DURVALUMAB (MEDI4736) in advanced HER-2 negative breast cancer: a pilot proof-of-concept trial | |||||||||||||
Medical condition: Advanced HER-2 negative breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000648-16 | Sponsor Protocol Number: BAY59-7939/19365 | Start Date*: 2017-06-21 | |||||||||||
Sponsor Name:Bayer AG | |||||||||||||
Full Title: Single-dose, open-label, randomized, 2-way crossover bioequivalence study of 10 mg granules for oral suspension rivaroxaban versus 10 mg tablets rivaroxaban under fasted condition in healthy subjects | |||||||||||||
Medical condition: Prevention and treatment of thromboembolic disorders | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001049-28 | Sponsor Protocol Number: VAC067 | Start Date*: 2017-05-26 |
Sponsor Name:University of Oxford, CTRG | ||
Full Title: A Phase I/II Study to assess the safety, immunogenicity and protective efficacy of novel malaria vaccine candidates ChAdOx1 LS2 and MVA LS2 in healthy UK adults | ||
Medical condition: Plasmodium falciparum infection | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-002826-11 | Sponsor Protocol Number: CWNT974X2102C | Start Date*: 2014-12-18 | |||||||||||
Sponsor Name:Array BioPharma Inc. | |||||||||||||
Full Title: A phase Ib/II multi-center, open label, dose escalation study of WNT974, LGX818 and cetuximab in patients with BRAFV600-mutant metastatic colorectal cancer harboring Wnt pathway mutations | |||||||||||||
Medical condition: colorectal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) ES (Completed) NL (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002900-10 | Sponsor Protocol Number: APD001 | Start Date*: 2016-01-29 |
Sponsor Name:UCB Celltech, UK Registered Branch of UCB Pharma SA | ||
Full Title: AN OPEN-LABEL EXPLORATORY STUDY OF UCB5857 IN SUBJECTS WITH ACTIVATED PHOSPHOINOSITIDE 3 KINASE (PI3K) DELTA SYNDROME (APDS) | ||
Medical condition: Activated PI3K delta Syndrome (APDS) | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: IT (Completed) DE (Completed) ES (Completed) FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-004882-26 | Sponsor Protocol Number: ND-L02-s0201-002 | Start Date*: 2015-03-25 | |||||||||||
Sponsor Name:Nitto Denko Corporation | |||||||||||||
Full Title: A Phase 1b/2, Open Label, Randomized, Repeat Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Biological Activity and Pharmacokinetics of ND L02 s0201 Injection, a Vitamin A-couple... | |||||||||||||
Medical condition: Moderate to extensive progressive hepatic fibrosis (METAVIR F3-4) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002100-83 | Sponsor Protocol Number: BH29812 | Start Date*: 2016-05-12 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF OBINUTUZUMAB IN COMBINATION WITH IDASANUTLIN IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA AND OBINUTUZUMAB OR RITUXIMAB IN C... | |||||||||||||
Medical condition: Relapsed or refractory (R/R) follicular lymphoma or diffuse large B-cell lymphoma. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002924-18 | Sponsor Protocol Number: 1517-CL-1001 | Start Date*: 2019-07-11 | |||||||||||
Sponsor Name:Astellas Pharma Global Development, Inc. (APGD) | |||||||||||||
Full Title: A Phase 1 Crossover Study to Assess the Relative Bioavailability of Roxadustat Following a Single Dose of Pediatric Azo Dye-free Tablet and Pediatric Azo Dye free Mini-tablet (Solid and Suspension)... | |||||||||||||
Medical condition: Healthy Adult Volunteers (intended indication is anemia associated with chronic kidney disease (CKD)) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.